News >

MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 28, 2019

Alison Schram, MD, a medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center

Alison Schram, MD

MCLA-128 (zenocutuzumab), an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and metastatic non–small cell lung cancer (NSCLC) who have NRG1 fusions, according to results presented during the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.1

All 3 patients who were treated with MCLA-128 experienced significant tumor shrinkage.

NRG1 fusions have recently been described in several cancer types and are enriched in diseases in desperate need of better therapy, including pancreatic and lung cancer,” Alison Schram, MD, a medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, stated in a press release.2 “Identifying a new, effective treatment strategy for these patients could make a big impact in their lives.”

... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x